KBRA Assigns Preliminary Ratings to Sequoia Mortgage Trust 2026-MED2 (SEMT 2026-MED2)

This is less a credit story than a funding-cost signal: if the market is willing to repackage niche borrower profiles into repeatable securitization, the economic winner is the originator with the best execution, not the borrower. That can widen gain-on-sale margins and lower warehouse dependence for lenders that can source affluent, high-FICO borrowers at scale; portfolio lenders and smaller local shops may lose pricing power if investors accept tighter spreads.

The second-order risk is that the label can outrun the data. These pools look low-loss on paper, but the real question is correlation: income is often tied to a single practice, local payer mix, specialty mix, and leverage on expensive homes. A healthcare reimbursement shock, practice consolidation, or broader housing softness would show up first in mezzanine tranches, long before anyone revises the “professional borrower” narrative.

Near term, this matters more for RMBS desks than public equities. The consensus is likely to overgeneralize one successful deal into a durable asset class; that is premature until there is seasoning and a second or third print with stable delinquencies. Falsifiers are simple: wider subordinate spreads on the next issue, rising early-payment defaults, or concentration in self-employed/low-documentation borrowers rather than true W-2 physician income.